EP2444071A1 — Minicapsule formulations
Assigned to Sigmoid Pharma Ltd · Expires 2012-04-25 · 14y expired
What this patent protects
A formulation comprises a plurality of seamless minicapsules, the minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having a core containing an active entity and an encapsulating body, the active entity being in the form of any one or more of:- ¢ a microem…
USPTO Abstract
A formulation comprises a plurality of seamless minicapsules, the minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having a core containing an active entity and an encapsulating body, the active entity being in the form of any one or more of:- ¢ a microemulsion, ¢ a nanoemulsion, ¢ a self-emulsifying delivery system, ¢ a self-microemulsifying delivery system, ¢ a biostable perflurocarbon formulation, ¢ a complex with cyclodextrin (and the like), ¢ liposomes, ¢ hydrogel, ¢ lymphatic targeted delivery system, ¢ liquid bi-layers, ¢ an aqueous system, ¢ wax, ¢ emzaloid, and ¢ natural plant extract.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.